PEOPLE - Enigma Diagnostics makes appointment:
This article was originally published in Clinica
Enigma Diagnostics, a UK company focused on developing rapid molecular diagnostics systems, has appointed Lynn Busteed as CEO. Dr Busteed joins the Porton Down firm from Focus Diagnostics (US), where she was vice-president for corporate development. Enigma recently appointed two other members of its executive management team: Biresh Roy as CFO and as an executive director on the board; and Mo Aslam as programme director (see Clinica No 1240, p 18).
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.